鼠李糖乳杆菌
炎症性肠病
益生菌
免疫系统
疾病
医学
免疫学
炎症性肠病
炎症
胃肠道
生物
内科学
细菌
遗传学
作者
Hang Guo,Leilei Yu,Fengwei Tian,Wei Chen,Qixiao Zhai
出处
期刊:Foods
[MDPI AG]
日期:2023-02-05
卷期号:12 (4): 692-692
标识
DOI:10.3390/foods12040692
摘要
Inflammatory bowel disease (IBD) is a heterogeneous group of diseases associated with chronic inflammation of the intestinal tract, and is highly prevalent worldwide. Although its origin is not yet fully understood, new evidence emphasizes that environmental factors, especially dietary factors and intestinal microbiota disorders are key triggers of IBD. Probiotics, such as Lactobacillaceae spp., play an essential role in human health as they exert beneficial effects on the composition of the human gastrointestinal microbial community and immune system. Probiotic-based therapies have been shown to be effective in alleviating IBD. Among these, Lactobacillaceae rhamnosus is one of the most widely used strains. L. rhamnosus is widely present in the intestines of healthy individuals; it regulates the intestinal immune system and reduces inflammation through a variety of mechanisms. The purpose of this study was to identify scientific evidence related to L. rhamnosus and IBD, review and summarize the results, and discuss the possible mechanisms of action as a starting point for future research on IBD treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI